AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29974571 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered misoprostol (S-Mis)
Number of subjects: 533
Study 29974571 — intervention group
Group type: COMPARATOR
Intervention: Hospital-administered misoprostol (H-Mis)
Number of subjects: 533
Study 28923084 — intervention group
Group type: EXPERIMENTAL
Intervention: TG4010 with standard chemotherapy
Number of subjects: 78
Study 28923084 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy alone
Number of subjects: 78
Study 28923084 — intervention group
Group type: EXPERIMENTAL
Intervention: TG4010
Number of subjects: 78
Study 26362774 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg oral dose of THCv
Number of subjects: 20
Study 26362774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23220014 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin threshold of 120 g/L (experimental arm)
Number of subjects: 6
Study 23220014 — intervention group
Group type: COMPARATOR
Intervention: Hemoglobin threshold of 70 g/L (control arm)
Number of subjects: 6
Study 21683161 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic consultation by a nurse (GrA), n = 123
Number of subjects: 244
Study 21683161 — intervention group
Group type: COMPARATOR
Intervention: Conventional clinical follow-up procedure (GrB), n = 121
Number of subjects: 244
Study 18294232 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately Loaded (IL) implants
Number of subjects: 12
Study 18294232 — intervention group
Group type: COMPARATOR
Intervention: Conventionally Loaded (CL) implants
Number of subjects: 12
Study 17312861 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic bubble trap (DBT)
Number of subjects: 60
Study 17312861 — intervention group
Group type: COMPARATOR
Intervention: Arterial filter (AF)
Number of subjects: 60
Study 15189624 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived continuation of the pre-merger group identity
Number of subjects: 0
Study 10984013 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg sodium valproate
Number of subjects: 12
Study 10984013 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg sodium valproate
Number of subjects: 12
Study 10984013 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg sodium valproate
Number of subjects: 12
Study 10984013 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg, 150 mg, and 300 mg sodium valproate
Number of subjects: 12
Study 9001327 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (SK) 250,000 IU
Number of subjects: 50
Study 9001327 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (UK) 100,000 IU
Number of subjects: 50
Study 8105943 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mEq/L calcium dialysate with oral calcitriol (median dose 0.25 microgram/day)
Number of subjects: 18
Study 8105943 — intervention group
Group type: COMPARATOR
Intervention: 3.5 mEq/L calcium dialysate without calcitriol
Number of subjects: 18
Study 8105943 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mEq/L calcium dialysate with oral calcitriol
Number of subjects: 18
Study 3310017 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg sodium hyaluronate
Number of subjects: 34
Study 3310017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 31504110 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid (AA) supplementation (tryptophan, leucine, and glutamine) for 16 weeks
Number of subjects: 0
Study 31504110 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid (AA) and multiple micronutrient (MM) supplementation for 16 weeks
Number of subjects: 0
Study 31504110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31504110 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid (AA) supplementation
Number of subjects: 0
Study 28087302 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0
Study 24448010 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Fox Test (MFT) with a workload of 110 W in the Study Group (n=60)
Number of subjects: 90
Study 24448010 — intervention group
Group type: COMPARATOR
Intervention: Application of modified regression norms in the Confirmatory Group (n=30)
Number of subjects: 90
Study 24290909 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietetic treatment
Number of subjects: 146
Study 21556830 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei treatment for 3 months
Number of subjects: 35
Study 21556830 — intervention group
Group type: COMPARATOR
Intervention: Control group (no probiotic treatment)
Number of subjects: 35
Study 19236785 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human interleukin 11 (rhIL‐11)
Number of subjects: 20
Study 19236785 — intervention group
Group type: COMPARATOR
Intervention: supporting treatment
Number of subjects: 20
Study 18001447 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 864
Study 18001447 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular methylergometrine
Number of subjects: 864
Study 15021279 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-soaked absorbable gelatin sponge (0.3 mg buprenorphine diluted to 5 mL with normal saline)
Number of subjects: 60
Study 15021279 — intervention group
Group type: COMPARATOR
Intervention: Absorbable gelatin sponge soaked with 5 mL normal saline (control group)
Number of subjects: 60
Study 15021279 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-soaked absorbable gelatin sponge
Number of subjects: 60
Study 12492609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous urotensin II infusion at 300 pmol min‐1
Number of subjects: 10
Study 12492609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous urotensin II infusion
Number of subjects: 10
Study 12492609 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study 9667477 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning brushing
Number of subjects: 30
Study 9667477 — intervention group
Group type: COMPARATOR
Intervention: Evening brushing
Number of subjects: 30
Study 7662780 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous mass polyglyconate (Maxon) double suture with loop
Number of subjects: 599
Study 7662780 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous mass polyglactin 910 (Vicryl)
Number of subjects: 599
Study 7662780 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted polyglactin 910 (Vicryl)
Number of subjects: 599
Study 7662780 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 599
Study 2516838 — intervention group
Group type: EXPERIMENTAL
Intervention: Aircast pneumatic air stirrup
Number of subjects: 40
Study 2516838 — intervention group
Group type: COMPARATOR
Intervention: Standard below‐knee walking cast
Number of subjects: 40
Study 785608 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 7
Study 785608 — intervention group
Group type: COMPARATOR
Intervention: Aspirin-Placebo
Number of subjects: 7
Study 6988115 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine
Number of subjects: 0
Study 6988115 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 30089762 — intervention group
Group type: EXPERIMENTAL
Intervention: Del Nido solution (DNS)
Number of subjects: 297
Study 30089762 — intervention group
Group type: COMPARATOR
Intervention: Intermittent warm blood cardioplegia (IWBC)
Number of subjects: 297
Study 28193369 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Intervention (MI)
Number of subjects: 302
Study 28193369 — intervention group
Group type: COMPARATOR
Intervention: Traditional Intervention (TI)
Number of subjects: 302
Study 26214684 — intervention group
Group type: EXPERIMENTAL
Intervention: Agricultural and finance intervention (human-powered water pump, microfinance loan, education in sustainable farming and financial management)
Number of subjects: 140
Study 26214684 — intervention group
Group type: EXPERIMENTAL
Intervention: Agricultural and finance intervention
Number of subjects: 140
Study 26214684 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 140
Study 23687089 — intervention group
Group type: EXPERIMENTAL
Intervention: Early immature gene expression signature
Number of subjects: 53
Study 23687089 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of bi-allelic TCRG deletion
Number of subjects: 53
Study 23687089 — intervention group
Group type: EXPERIMENTAL
Intervention: CD13 surface expression
Number of subjects: 53
Study 23687089 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygous deletions of the short arm of chromosome 17
Number of subjects: 53
Study 23687089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in IDH1/IDH2 and DNMT3A genes
Number of subjects: 53
Study 23687089 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of CD8 or CD62L
Number of subjects: 53
Study 23687089 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous deletion of CDKN2A/CDKN2B
Number of subjects: 53
Study 23687089 — intervention group
Group type: EXPERIMENTAL
Intervention: NOTCH1 and/or FBXW7 mutations
Number of subjects: 53
Study 23687089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations or deletions in the BCL11B tumor suppressor gene
Number of subjects: 53
Study 23687089 — intervention group
Group type: EXPERIMENTAL
Intervention: CD13 expression and homozygous CDKN2A/CDKN2B deletions
Number of subjects: 53
Study 23687089 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutations in IDH1/IDH2 and DNMT3A
Number of subjects: 53
Study 21221988 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with Down syndrome (DS)
Number of subjects: 40
Study 21221988 — intervention group
Group type: COMPARATOR
Intervention: Individuals without Down syndrome (non-DS)
Number of subjects: 40
Study 19661687 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml of vinegar (750 mg AcOH)
Number of subjects: 0
Study 19661687 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml of vinegar (1,500 mg AcOH)
Number of subjects: 0
Study 19661687 — intervention group
Group type: COMPARATOR
Intervention: 0 ml of vinegar (0 mg AcOH, placebo)
Number of subjects: 0
Study 17370665 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) with Atrisorb membrane
Number of subjects: 31
Study 17370665 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement
Number of subjects: 31
Study 15220300 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (40 min of stationary cycling, 4 times/week for 8 weeks)
Number of subjects: 16
Study 15220300 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary patients, n = 15)
Number of subjects: 16
Study 11888224 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (18.75 mg daily, increased by one tablet at 1 week intervals)
Number of subjects: 13
Study 11888224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11888224 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine and Placebo
Number of subjects: 13
Study 9863332 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical application of 0.5 mg Dinoprostone (Group I)
Number of subjects: 90
Study 9863332 — intervention group
Group type: COMPARATOR
Intervention: Intravenous application of Syntocinon (Group II)
Number of subjects: 90
Study 9863332 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group I and Group II)
Number of subjects: 90
Study 9863332 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods of labor induction (Group I and Group II)
Number of subjects: 90
Study 7675391 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic strategies (not specified)
Number of subjects: 0
Study 7675391 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (anticoagulant of choice)
Number of subjects: 0
Study 7675391 — intervention group
Group type: COMPARATOR
Intervention: Consensus recommendations (not specified)
Number of subjects: 0
Study 2116057 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (200 micrograms, as an i.v. bolus)
Number of subjects: 30
Study 2116057 — intervention group
Group type: COMPARATOR
Intervention: Control saline (in isovolumic amount)
Number of subjects: 30
Study 146331 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus heparin
Number of subjects: 49
Study 146331 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 49
Study 29868722 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent overnight travel
Number of subjects: 906
Study 29868722 — intervention group
Group type: EXPERIMENTAL
Intervention: Not using an insecticide‐treated net during travel
Number of subjects: 906
Study 29868722 — intervention group
Group type: EXPERIMENTAL
Intervention: Young age (children)
Number of subjects: 906
Study 28004188 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (15 mg/kg/6 h IV infusion for 3 days)
Number of subjects: 300
Study 28004188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg IV infusion followed by 5 mg/kg/day for 2 days)
Number of subjects: 300
Study 28004188 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg/12 h IV infusion for three doses)
Number of subjects: 300
Study 28004188 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study 26342584 — intervention group
Group type: EXPERIMENTAL
Intervention: Double List Experiment (List A and List B)
Number of subjects: 3219
Study 24308191 — intervention group
Group type: COMPARATOR
Intervention: Cervical paravertebral block (control) group
Number of subjects: 60
Study 24308191 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus cervical paravertebral block (acupuncture) group
Number of subjects: 60
Study 22018631 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole monotherapy for 5 years
Number of subjects: 8010
Study 22018631 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen monotherapy for 5 years
Number of subjects: 8010
Study 22018631 — intervention group
Group type: COMPARATOR
Intervention: Letrozole followed by tamoxifen (2 years letrozole, 3 years tamoxifen)
Number of subjects: 8010
Study 22018631 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen followed by letrozole (2 years tamoxifen, 3 years letrozole)
Number of subjects: 8010
Study 19886855 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 150/12.5 mg to 300/25 mg
Number of subjects: 695
Study 19886855 — intervention group
Group type: COMPARATOR
Intervention: Irbesartan 150 mg to 300 mg
Number of subjects: 695
Study 16143443 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint
Number of subjects: 21
Study 16143443 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 21
Study 15378542 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving training (PST)
Number of subjects: 212
Study 15378542 — intervention group
Group type: COMPARATOR
Intervention: Client-centered counseling
Number of subjects: 212
Study 15378542 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing negative for BRCA1/2 mutation
Number of subjects: 212
Study 15378542 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing positive for BRCA1/2 mutation
Number of subjects: 212
Study 15378542 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-testers
Number of subjects: 212
Study 15378542 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal history of cancer
Number of subjects: 212
Study 12197793 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaiser Permanente Colorado Asthma Care Management Program
Number of subjects: 298
Study 12197793 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 298
Study 9768826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane (DEX) administered 30 minutes before daunorubicin (DNR) 45 mg/m2 or mitoxantrone (MTX) 10 mg/m2, in doses 8-13 times higher for DNR or 30-60 times higher for MTX, with a treatment cycle including 10 high doses (2,000 mg/m2/12 hr) of cytosine arabinoside plus two doses of DNR or MTX on days 4 and 5.
Number of subjects: 8
Study 9768826 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane (DEX) as a cardioprotective agent during chemotherapy.
Number of subjects: 8
Study 9768826 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed administration of DEX after cumulative doses of DNR 500 mg/m2.
Number of subjects: 8
Study 9768826 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen including DEX, DNR, MTX, and cytosine arabinoside.
Number of subjects: 8
Study 8576413 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable speech appliance developed by Clark, Schwarz, and Blakeley (1993)
Number of subjects: 0
Study 2667633 — intervention group
Group type: COMPARATOR
Intervention: Propantheline bromide
Number of subjects: 23
Study 2667633 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutinin hydrochloride and Propantheline bromide
Number of subjects: 23
Study 408860 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan treatment
Number of subjects: 0
Study 30901920 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg nicotine of TC (3TC)
Number of subjects: 24
Study 30901920 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg nicotine of EC (3EC)
Number of subjects: 24
Study 30901920 — intervention group
Group type: COMPARATOR
Intervention: Control 0 mg nicotine of EC (C)
Number of subjects: 24
Study 30400586 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (vitamins C, E, D, zinc, beta-carotene, lutein, zeaxanthin, omega-3 fatty acids)
Number of subjects: 300000000
Study 30400586 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary habits (high-fat and high-glucose or -fructose diets)
Number of subjects: 300000000
Study 26679253 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 0
Study 26679253 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 0
Study 25332492 — intervention group
Group type: EXPERIMENTAL
Intervention: CEASE intervention
Number of subjects: 20
Study 25332492 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study 22301466 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week pegylated interferon plus ribavirin therapy
Number of subjects: 662
Study 19490745 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (high-quality studies)
Number of subjects: 115
Study 19490745 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy (lower-quality studies)
Number of subjects: 115
Study 16763372 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum total homocysteine levels
Number of subjects: 3090
Study 16763372 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 5 mumol/l increment in homocysteine levels
Number of subjects: 3090
Study 16763372 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for age and gender)
Number of subjects: 3090
Study 16303792 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (66 mg/m² Day 1)
Number of subjects: 50
Study 16303792 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (33 mg/m² Days 1 and 8)
Number of subjects: 50
Study 16303792 — intervention group
Group type: COMPARATOR
Intervention: Both arms (A and B)
Number of subjects: 50
Study 16303792 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (66 mg/m² Day 1)
Number of subjects: 50
Study 16303792 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (33 mg/m² Days 1 and 8)
Number of subjects: 50
Study 16303792 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to front-line chemotherapy
Number of subjects: 50
Study 12010910 — intervention group
Group type: EXPERIMENTAL
Intervention: POTS patients with high venous pressure (P(v)>20 mm Hg)
Number of subjects: 15
Study 12010910 — intervention group
Group type: EXPERIMENTAL
Intervention: POTS patients with normal venous pressure
Number of subjects: 15
Study 12010910 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study 10051277 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (100 microgram/puff)
Number of subjects: 18
Study 10051277 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 18
Study 10051277 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 18
Study 10155119 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion balloon as a primary dilation device
Number of subjects: 0
Study 10155119 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion balloon as a primary device
Number of subjects: 0
Study 10155119 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary perfusion angioplasty with stent bailout when needed
Number of subjects: 0
Study 10155119 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion balloon
Number of subjects: 0
Study 10155119 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion angioplasty as a primary treatment strategy
Number of subjects: 0
Study 10155119 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion balloon as an initial device
Number of subjects: 0
Study 2288830 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ml cream (20 g fat) preload with placebo
Number of subjects: 12
Study 2288830 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 ml cream (20 g fat) preload with 10 mg cisapride
Number of subjects: 12
Study 2288830 — intervention group
Group type: COMPARATOR
Intervention: 50 ml water preload with placebo
Number of subjects: 12
Study 6966082 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 20
Study 6966082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6966082 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 20
Study 31864932 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 100
Study 31864932 — intervention group
Group type: COMPARATOR
Intervention: Mechanochemical ablation (MOCA)
Number of subjects: 100
Study 30975055 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent Electrical Stimulation (MES)
Number of subjects: 45
Study 30975055 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 45
Study 30975055 — intervention group
Group type: COMPARATOR
Intervention: Standard Wound Care (Control)
Number of subjects: 45